The Hong Kong stock market has recently seen a surge in IPO filings. According to incomplete statistics from Xinfeng, no fewer than 20 companies have submitted IPO applications to the Hong Kong Stock Exchange since May of this year, with Xi’an Dayi Group Co., Ltd. being one of them. Dayi Group specializes in gamma knife and other radiotherapy products, primarily for patients with tumors, and this potential market prospect has attracted investment from over 10 star investment institutions, including Hillhouse. In 2024, Dayi Group’s gamma knife sales accounted for 75.8% of the domestic market, ranking first in the industry.
Risk warning and disclaimer: The market is risky and investment should be made with caution. This article does not constitute personal investment advice and has not taken into account individual users’ specific investment objectives, financial conditions, or needs. Users should consider whether any opinions, views, or conclusions in this article match their particular situation. Investment based on this article is at one’s own risk.
